Viemed Healthcare, Inc. filed a Current Report on Form 8-K with the SEC on November 4, 2026, disclosing its financial results for the three and nine months ended September 30, 2026, along with a Financial Supplement and an Investor Deck Presentation.
Tutor Perini Corporation filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 4, 2026, reporting third-quarter revenue of $1,720,256 thousand and net income attributable to the company of $20,701 thousand.
Tutor Perini Corporation filed a Form 8-K with the SEC on November 4, 2026, disclosing the issuance of a press release announcing its financial results for the quarter ended September 30, 2026.
AppLovin Corporation filed a Form 8-K on November 4, 2026, disclosing that certain stockholders approved a reincorporation from Delaware to Nevada by written consent on October 29, 2026, and separately announced financial results for the quarter ended September 30, 2026.
Summit Therapeutics Inc. filed a current report on November 4, 2026, to submit the legal opinion of Baker & Hostetler LLP relating to the legality of a common stock issuance connected to a prospectus supplement filed under the company's automatic shelf registration statement.
Summit Therapeutics Inc. filed a Form 8-K on November 4, 2026, disclosing a stockholder-approved amendment to its Restated Certificate of Incorporation that doubles authorized common stock from 1,000,000,000 to 2,000,000,000 shares, alongside the release of its third-quarter 2026 financial results.
Summit Therapeutics Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026, with the SEC on November 4, 2026, disclosing condensed consolidated financial statements and related information.
Ascent Industries Co. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 4, 2026, reporting a return to operating income from continuing operations in the third quarter.
Geron Corporation filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 4, 2026, reporting its first quarterly net income since the commercial launch of RYTELO.
Vir Biotechnology, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 4, 2026, reporting condensed consolidated financial statements for the third quarter and nine months ended September 30, 2026.